TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Creative Planning

Creative Planning lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 11.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,262 shares of the company’s stock after purchasing an additional 1,089 shares during the period. Creative Planning’s holdings in TransMedics Group were worth $1,611,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TMDX. Sapient Capital LLC purchased a new position in TransMedics Group in the third quarter valued at $1,241,000. USA Financial Formulas acquired a new stake in TransMedics Group in the 3rd quarter valued at about $55,000. Handelsbanken Fonder AB boosted its stake in shares of TransMedics Group by 657.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock valued at $10,111,000 after buying an additional 55,900 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of TransMedics Group during the second quarter worth about $372,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of TransMedics Group during the second quarter worth approximately $420,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on TMDX. Stephens lifted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective on shares of TransMedics Group in a research report on Tuesday. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC decreased their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Canaccord Genuity Group lowered their price objective on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $88.50 on Wednesday. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of 94.15 and a beta of 1.99. The stock’s 50-day moving average is $146.02 and its two-hundred day moving average is $140.16.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter in the prior year, the business earned ($0.12) EPS. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. Analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock worth $9,981,907 in the last 90 days. 7.00% of the stock is owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.